| P2093 | author name string | Ilker Tasci | |
| | Selim Kilic | |
| | Alper Sonmez | |
| | Mahmut Ilker Yilmaz | |
| | Serkan Tapan | |
| | Cemal Nuri Ercin | |
| | Teoman Dogru | |
| | Gokhan Erdem | |
| | Mustafa Kutlu | |
| | Mehmet Kemal Erbil | |
| | Gurkan Celebi | |
| | Halil Genc | |
| | Gokhan Uckaya | |
| P2860 | cites work | Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor | Q22004174 |
| | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 |
| | Characterization of apelin, the ligand for the APJ receptor | Q28141574 |
| | The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism | Q28198114 |
| | The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats | Q28205696 |
| | Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility | Q28221294 |
| | Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo | Q28256865 |
| | Modification of the terminal residue of apelin-13 antagonizes its hypotensive action | Q28287993 |
| | Apelin is a novel angiogenic factor in retinal endothelial cells | Q28291991 |
| | Apelin, a newly identified adipokine up-regulated by insulin and obesity | Q28304725 |
| | [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man | Q28360176 |
| | Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats | Q28583950 |
| | Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? | Q36235965 |
| | ADMA: its role in vascular disease | Q36380994 |
| | ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. | Q36677348 |
| | Apelin and cardiac function in hemodialyzed patients: possible relations? | Q40341428 |
| | Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia | Q42538581 |
| | Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus | Q43796150 |
| | Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 |
| | Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor | Q43922999 |
| | Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure | Q44546796 |
| | LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia | Q46323342 |
| | Vascular effects of apelin in vivo in man. | Q46389030 |
| | Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome | Q46494570 |
| | Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus | Q46592249 |
| | Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension | Q46626286 |
| | Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells | Q47993319 |
| | Plasma apelin is lower in patients with elevated LDL-cholesterol. | Q51467188 |
| | Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). | Q51772805 |
| P433 | issue | 3 | |
| P921 | main subject | arterial hypertension | Q41861 |
| P304 | page(s) | 179-183 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Clinical and Experimental Hypertension | Q5133806 |
| P1476 | title | Plasma apelin and ADMA Levels in patients with essential hypertension | |
| P478 | volume | 32 | |